Century Therapeutics vs Xencor
Xencor is the larger business, with $126m of revenue in fiscal 2025 against $109m for Century Therapeutics (1.2 times as much). Century Therapeutics grew faster (1556.8% against 13.7%). Century Therapeutics kept more of each dollar of sales as profit: a net margin of -8.8% against -73.2%.
| Latest fiscal year | Century TherapeuticsIPSC, 2025 | XencorXNCR, 2025 |
|---|---|---|
| Revenue | $109m | $126m |
| Revenue growth | 1556.8% | 13.7% |
| Net income | −$9.6m | −$91.9m |
| Operating margin | -15.8% | — |
| Net margin | -8.8% | -73.2% |
| Return on equity | -6.0% | -14.0% |
| Free cash flow | −$105m | −$138m |
| Cash | $61.9m | $54.1m |
| Total debt | $0 | $120m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 78 | 260 |
| Market value | $274m | $2.29bn |
| Price vs our value range | — | — |
| Moat score | — | 11 (Weak) |
| Insider trades, 12 months | 3 buys, 20 sales | 0 buys, 18 sales |